- Previous Close
21.80 - Open
20.80 - Bid 21.20 x --
- Ask 22.40 x --
- Day's Range
20.00 - 22.60 - 52 Week Range
16.00 - 41.00 - Volume
9,919 - Avg. Volume
7,074 - Market Cap (intraday)
260.652M - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-8.21 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
60.00
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
guardtherapeutics.comRecent News: GUARD.ST
View MorePerformance Overview: GUARD.ST
Trailing total returns as of 1/27/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUARD.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUARD.ST
View MoreValuation Measures
Market Cap
268.03M
Enterprise Value
201.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.41%
Return on Equity (ttm)
-87.28%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-78.82M
Diluted EPS (ttm)
-8.21
Balance Sheet and Cash Flow
Total Cash (mrq)
91.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-52.08M